Publications
The material below is provided to support scientific exchange. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.
For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.
Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study
Publication Details
Orphanet Journal of Rare Diseases
October 2024
Author(s)
Eliane Sardh1, Manisha Balwani2, David C Rees3, Karl E Anderson4, Gang Jia5, Marianne T Sweetser6, Bruce Wang7
Affiliations
1CMMS - Centre for Inherited Metabolic Diseases, Karolinska University Hospital, Karolinska Institutet, Solna, 171 64, Stockholm, Sweden; 2Department of Genetics and Genomic Sciences, Icahn School of Medicine, New York, NY, USA; 3Comprehensive Cancer Centre, King's College Hospital, London, UK; 4Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Texas Medical Branch, Galveston, TX, USA; 5Medical Affairs Statistics, Alnylam Pharmaceuticals, Cambridge, MA, USA; 6Clinical Development, Alnylam Pharmaceuticals, Cambridge, MA, USA; 7Department of Medicine and UCSF Liver Center, University of California San Francisco, San Francisco, CA, USA
Abstract
Background:
Acute hepatic porphyria is a group of multisystem disorders of which acute intermittent porphyria is the most common subtype. Givosiran, a subcutaneously administered RNA interference therapeutic targeting liver ALAS mRNA, is approved for treating these disorders. This Phase 1/2 open-label extension study (NCT02949830) evaluated the long-term safety and efficacy of givosiran in adults with acute intermittent porphyria, with follow-up of up to 48 months, which is the longest follow-up of givosiran treatment to date. Participants were adults aged 18–65 years who completed part C of the Phase 1 givosiran study (NCT2452372).
Methods:
Enrollees received givosiran for up to 48 months. Primary and secondary endpoints included the incidence of adverse events, changes in urinary delta-aminolevulinic acid (ALA) and porphobilinogen (PBG) levels, annualized rate of porphyria attacks, and annualized hemin use. Quality of life was assessed using the EQ-5D-5L instrument as an exploratory endpoint.
Results:
Sixteen patients (median age: 39.5 years) participated. Common adverse events included abdominal pain, nasopharyngitis, and nausea (50% each), with injection-site erythema (38%) and injection-site pruritus (25%) noted as frequent treatment-related reactions. Givosiran therapy reduced annualized rates of porphyria attacks and hemin use by 97% and 96%, respectively. From months > 33 to 48, all patients were free from attacks requiring significant medical intervention and did not use hemin. There were substantial reductions in median urinary ALA and PBG of 95% and 98%, respectively. Additionally, a clinically meaningful improvement in quality of life was observed.
Conclusions:
In the longest follow-up of givosiran-treated patients reported to date, the therapy maintained an acceptable safety profile and demonstrated sustained improvements in clinical outcomes over 4 years in patients with acute intermittent porphyria.
PMID
39363243
DOI
10.1186/s13023-024-03284-w
Publication Materials
Visit website/URL/link
Manuscript
